Because the original Dallas Heart Study cohort was diverse, they recognised the increased frequency of the PNPLA3 I148M pathogenic variant in the Hispanic subset of their patients [129] who are at higher risk for NAFLD than other ethnic groups. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.